185 related articles for article (PubMed ID: 22472121)
1. Histone deacetylase inhibitors influence chemotherapy transport by modulating expression and trafficking of a common polymorphic variant of the ABCG2 efflux transporter.
Basseville A; Tamaki A; Ierano C; Trostel S; Ward Y; Robey RW; Hegde RS; Bates SE
Cancer Res; 2012 Jul; 72(14):3642-51. PubMed ID: 22472121
[TBL] [Abstract][Full Text] [Related]
2. Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2.
Mizuarai S; Aozasa N; Kotani H
Int J Cancer; 2004 Mar; 109(2):238-46. PubMed ID: 14750175
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer resistance protein (BCRP)-mediated glyburide transport: effect of the C421A/Q141K BCRP single-nucleotide polymorphism.
Pollex EK; Anger G; Hutson J; Koren G; Piquette-Miller M
Drug Metab Dispos; 2010 May; 38(5):740-4. PubMed ID: 20159988
[TBL] [Abstract][Full Text] [Related]
4. Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2.
Tamura A; Wakabayashi K; Onishi Y; Takeda M; Ikegami Y; Sawada S; Tsuji M; Matsuda Y; Ishikawa T
Cancer Sci; 2007 Feb; 98(2):231-9. PubMed ID: 17297656
[TBL] [Abstract][Full Text] [Related]
5. The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance.
Shi Z; Parmar S; Peng XX; Shen T; Robey RW; Bates SE; Fu LW; Shao Y; Chen YM; Zang F; Chen ZS
Oncol Rep; 2009 Feb; 21(2):483-9. PubMed ID: 19148526
[TBL] [Abstract][Full Text] [Related]
6. Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin.
Chearwae W; Shukla S; Limtrakul P; Ambudkar SV
Mol Cancer Ther; 2006 Aug; 5(8):1995-2006. PubMed ID: 16928820
[TBL] [Abstract][Full Text] [Related]
7. Single nucleotide polymorphisms modify the transporter activity of ABCG2.
Morisaki K; Robey RW; Ozvegy-Laczka C; Honjo Y; Polgar O; Steadman K; Sarkadi B; Bates SE
Cancer Chemother Pharmacol; 2005 Aug; 56(2):161-72. PubMed ID: 15838659
[TBL] [Abstract][Full Text] [Related]
8. Contrasting roles of the ABCG2 Q141K variant in prostate cancer.
Sobek KM; Cummings JL; Bacich DJ; O'Keefe DS
Exp Cell Res; 2017 May; 354(1):40-47. PubMed ID: 28300564
[TBL] [Abstract][Full Text] [Related]
9. Potential role of cyclooxygenase-2 on the regulation of the drug efflux transporter ABCG2 in breast cancer cell lines.
Kalalinia F; Elahian F; Behravan J
J Cancer Res Clin Oncol; 2011 Feb; 137(2):321-30. PubMed ID: 20422426
[TBL] [Abstract][Full Text] [Related]
10. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients.
Li J; Cusatis G; Brahmer J; Sparreboom A; Robey RW; Bates SE; Hidalgo M; Baker SD
Cancer Biol Ther; 2007 Mar; 6(3):432-8. PubMed ID: 17312388
[TBL] [Abstract][Full Text] [Related]
11. Multiple drugbinding sites on the R482G isoform of the ABCG2 transporter.
Clark R; Kerr ID; Callaghan R
Br J Pharmacol; 2006 Nov; 149(5):506-15. PubMed ID: 16981002
[TBL] [Abstract][Full Text] [Related]
12. Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations.
Furukawa T; Wakabayashi K; Tamura A; Nakagawa H; Morishima Y; Osawa Y; Ishikawa T
Pharm Res; 2009 Feb; 26(2):469-79. PubMed ID: 18958403
[TBL] [Abstract][Full Text] [Related]
13. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.
Cotte S; von Ahsen N; Kruse N; Huber B; Winkelmann A; Zettl UK; Starck M; König N; Tellez N; Dörr J; Paul F; Zipp F; Lühder F; Koepsell H; Pannek H; Montalban X; Gold R; Chan A
Brain; 2009 Sep; 132(Pt 9):2517-30. PubMed ID: 19605531
[TBL] [Abstract][Full Text] [Related]
14. The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms.
Natarajan K; Bhullar J; Shukla S; Burcu M; Chen ZS; Ambudkar SV; Baer MR
Biochem Pharmacol; 2013 Feb; 85(4):514-24. PubMed ID: 23261525
[TBL] [Abstract][Full Text] [Related]
15. The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells.
Kim M; Turnquist H; Jackson J; Sgagias M; Yan Y; Gong M; Dean M; Sharp JG; Cowan K
Clin Cancer Res; 2002 Jan; 8(1):22-8. PubMed ID: 11801536
[TBL] [Abstract][Full Text] [Related]
16. Single-nucleotide polymorphisms of ABCG2 increase the efficacy of tyrosine kinase inhibitors in the K562 chronic myeloid leukemia cell line.
Skoglund K; Boiso Moreno S; Jönsson JI; Vikingsson S; Carlsson B; Gréen H
Pharmacogenet Genomics; 2014 Jan; 24(1):52-61. PubMed ID: 24322003
[TBL] [Abstract][Full Text] [Related]
17. BCRP/
Wen X; Kozlosky D; Zhang R; Doherty C; Buckley B; Barrett E; Aleksunes LM
Drug Metab Dispos; 2021 Aug; 49(8):629-637. PubMed ID: 34074729
[TBL] [Abstract][Full Text] [Related]
18. Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes.
Calcagno AM; Fostel JM; To KK; Salcido CD; Martin SE; Chewning KJ; Wu CP; Varticovski L; Bates SE; Caplen NJ; Ambudkar SV
Br J Cancer; 2008 May; 98(9):1515-24. PubMed ID: 18382425
[TBL] [Abstract][Full Text] [Related]
19. Impact of genetic variability in the ABCG2 gene on ABCG2 expression, function, and interaction with AT1 receptor antagonist telmisartan.
Deppe S; Ripperger A; Weiss J; Ergün S; Benndorf RA
Biochem Biophys Res Commun; 2014 Jan; 443(4):1211-7. PubMed ID: 24388985
[TBL] [Abstract][Full Text] [Related]
20. A 96-well efflux assay to identify ABCG2 substrates using a stably transfected MDCK II cell line.
Xiao Y; Davidson R; Smith A; Pereira D; Zhao S; Soglia J; Gebhard D; de Morais S; Duignan DB
Mol Pharm; 2006; 3(1):45-54. PubMed ID: 16686368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]